1. Home
  2. DK vs ZYME Comparison

DK vs ZYME Comparison

Compare DK & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DK
  • ZYME
  • Stock Information
  • Founded
  • DK 2001
  • ZYME 2003
  • Country
  • DK United States
  • ZYME United States
  • Employees
  • DK N/A
  • ZYME N/A
  • Industry
  • DK Integrated oil Companies
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • DK Energy
  • ZYME Health Care
  • Exchange
  • DK Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • DK 1.0B
  • ZYME 846.1M
  • IPO Year
  • DK 2006
  • ZYME 2017
  • Fundamental
  • Price
  • DK $15.36
  • ZYME $11.31
  • Analyst Decision
  • DK Hold
  • ZYME Buy
  • Analyst Count
  • DK 12
  • ZYME 6
  • Target Price
  • DK $16.75
  • ZYME $19.50
  • AVG Volume (30 Days)
  • DK 1.4M
  • ZYME 553.2K
  • Earning Date
  • DK 05-07-2025
  • ZYME 05-08-2025
  • Dividend Yield
  • DK 6.69%
  • ZYME N/A
  • EPS Growth
  • DK N/A
  • ZYME N/A
  • EPS
  • DK N/A
  • ZYME N/A
  • Revenue
  • DK $11,366,100,000.00
  • ZYME $93,384,000.00
  • Revenue This Year
  • DK N/A
  • ZYME $26.29
  • Revenue Next Year
  • DK N/A
  • ZYME $75.78
  • P/E Ratio
  • DK N/A
  • ZYME N/A
  • Revenue Growth
  • DK N/A
  • ZYME 85.05
  • 52 Week Low
  • DK $11.03
  • ZYME $8.21
  • 52 Week High
  • DK $29.14
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • DK 63.57
  • ZYME 40.96
  • Support Level
  • DK $13.29
  • ZYME $10.86
  • Resistance Level
  • DK $14.08
  • ZYME $13.23
  • Average True Range (ATR)
  • DK 0.70
  • ZYME 0.56
  • MACD
  • DK 0.34
  • ZYME -0.10
  • Stochastic Oscillator
  • DK 89.98
  • ZYME 18.78

About DK Delek US Holdings Inc.

Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. Delek's logistics segment sells portions of the petroleum products its refineries produce. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: